Scientists have developed a groundbreaking test that can detect 18 early-stage cancers, potentially representing a significant advancement in medical diagnostics.…
Browsing: Liquid Biopsy
PanGIA Biotech, a US-based biotechnology company, is finalizing a three-year, prospective, multicenter clinical study on prostate cancer liquid biopsy and…
Geneoscopy and Adiso Therapeutics have entered into a strategic collaboration to use Geneoscopy’s stool-based transcriptome platform in a Phase II…
Mainz Biomed N.V., a molecular genetics diagnostic company, has announced significant topline results from its eAArly DETECT U.S. clinical study.…
Cancer Research UK and Guardant Health have initiated a collaborative effort focused on advancing cancer research and clinical development activities.…
A study on the cost-effectiveness of liquid biopsy compared to colonoscopy for colorectal cancer (CRC) screening. Here’s a summary of…
The “ColoSense” multitarget stool RNA test has demonstrated superior sensitivity and specificity for detecting colorectal cancer and advanced adenomas compared…
A recent study conducted by the Regenstrief Institute and led by Research Scientist Thomas F. Imperiale, M.D., suggests that a…
This research, published in Cell Reports Medicine, explores the potential of circulating cell-free RNA (cfRNA) in blood plasma as a…
Universal DX (UDX), a liquid biopsy firm, successfully closes a Series B financing round of approximately $70 million. Key highlights…